PA
GHDX

Parallel Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Parallel Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-925
Closed -$26K – 2190
2017
Q3 		$26K Buy
+925
New +$29.2K ﹤0.01% 905

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Parallel Advisors's GHDX Position: Q4 2017 in Review

Parallel Advisors sold out of Genomic Health, Inc. (GHDX) in Q4 2017, closing a stake of 925 shares — an estimated $26K sold.

Parallel Advisors first reported a position in GHDX in Q3 2017 and held it in 1 quarter. The position peaked at $26K in Q3 2017. 135 funds tracked by Wall St. Rank hold GHDX as of Q4 2017.

  • Parallel Advisors reported no remaining Genomic Health, Inc. position as of Q4 2017 after selling out during the quarter.
  • Parallel Advisors sold 925 Genomic Health, Inc. shares in Q4 2017, an estimated $26K.
  • Parallel Advisors first reported a position in Genomic Health, Inc. in Q3 2017 and held it in 1 quarter.
  • Parallel Advisors's Genomic Health, Inc. position peaked at $26K in Q3 2017.
  • 135 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2017.

Based on Parallel Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.